VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin
17 Nov 2022
Clinical ResultPhase 3Drug ApprovalNDA
Currently the Only Long-Acting Growth Hormone Demonstrates Superior Annualized Height Velocity Compared to Daily hGH in Children with Growth Hormone Deficiency
SHANGHAI, Nov. 17, 2022 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, today released for the first time detailed clinical data from its pivotal Phase 3 study of lonapegsomatropin, a long-acting prodrug of unmodified somatropin being investigated as a once-weekly injection in children with growth hormone deficiency (GHD) in China.
The data showed that lonapegsomatropin demonstrated an annualized height velocity (AHV) of 10.66 cm/year compared to 9.75 cm/year for the daily hGH at 52 weeks (treatment difference at 0.91 cm/year with a 95 percent confidence interval: 0.37 – 1.45 cm/year, p=0.0010), reaching its primary objective, demonstrating that lonapegsomatropin is non-inferior to the daily hGH. Further analysis showed that lonapegsomatropin had superior efficacy to the daily hGH. Multiple pre-set sensitivity analyses validated the robustness of these results.
During this trial, lonapegsomatropin was well tolerated with a safety profile comparable to daily hGHhGH.
Currently, most of the commercially available growth hormone therapies in China are in the form of short-acting daily injections.
Lonapegsomatropin is in development in Greater China through license from Ascendis Pharma and uses Ascendis Pharma's innovative TransCon[1] (Transient Conjugation) technology.
When injected, physiologic conditions in the body initiate the release of the active, unmodified somatropin in a predictable manner at a predetermined rate, releasing predictable levels of somatropin over the course of the week.
VISEN's pivotal Phase 3 trial was a randomized, open-label, active-controlled trial with children suffering from growth hormone deficiency in China led by Professor Luo Xiaoping as the principal investigator, the Deputy Director of the Pediatrics Commission of China Medical Association and Director of the Pediatrics Department at Tongji Hospital affiliated to the Huazhong University of Science and Technology.
Elaborating on the clinical trial data, Professor Luo Xiaoping further commented: "The AHV was significantly higher for lonapegsomatropin than for the daily hGH from week 13 onward. Height standard deviation score (SDS) [2]at 52 weeks increased over baseline by 1.01 for lonapegsomatropin and by 0.83 for the daily hGH (p=0.0015). In addition, the improvement of height SDS in the lonapegsomatropin group is more significant from week 13 onward. Over 52 weeks of treatment, insulin-like growth factor-1 (IGF-1) generally increased into the normal range and mean average IGF-1 SDS values in the lonapegsomatripin group was greater than daily rhGH. IGF-1 is a polypeptide produced by the liver in response to GH, and its physiological role is mainly to stimulate chondrocyte proliferation, differentiation, and collagen synthesis[3]. The augmentative/counteractive system of GHIGF augments the anabolic action of GH while attenuating the potentially undesirable GH effects of gluconeogenesis and lipolysis[4]."
Pony LU, CEO and Executive Director of VISEN Pharmaceuticals, said: "According to publicly available data of marketed products in China, lonapegsomatropin is currently the only long-acting growth hormone demonstrated superiority to the daily treatment with the growth hormone somatropin. The pivotal 52-week data released today from the China Phase 3 clinical trial demonstrated head-to-head that once-weekly lonapegsomatropin is non-inferiority and superior to daily hGH. The results are consistent with Ascendis Pharma's global pivotal Phase 3 heiGHt Trial, and we look forward to offering a new long-acting growth hormone treatment option for Chinese patients."
Lonapegsomatropin is globally developed by Ascendis Pharma A/S, who received U.S. Food and Drug Administration (FDA) and the European Commission (EC) approval for lonapegsomatropin in pediatric growth hormone deficiency in August 2021 and January 2022, respectively.
About VISEN Pharmaceuticals
VISEN is an innovative biopharmaceutical company focused on endocrine diseases. We are dedicated to providing innovative therapies and compassionate, patient-centric care, because we believe that achieving better treatment processes and outcomes results in living better lives. Putting patients' need first, VISEN is committed to providing first-in-class or best-in-class products and treatments for endocrine diseases. Our therapeutic areas cover endocrine diseases in adults and children, and rare endocrine diseases.
VISEN comprises seasoned professionals with multinational pharmaceutical experiences and leverages cutting-edge technologies and leading resources across the world. We are focused on the Chinese market, and have established offices in Shanghai, Beijing, Hong Kong and Taipei. We have also launched our Greater China R&D and Manufacturing Campus in Suzhou to enhance R&D, manufacturing and commercialization efforts. Our goal is to enable Chinese endocrine patients to benefit from the world's most advanced and reliable treatment solutions earlier.
For more information, please visit our website: http://www.visenpharma.com/
SOURCE VISEN Pharmaceuticals
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.